NAVIDEA BIOPHARMACEUTICALS news, videos and press releases
For more news please use our advanced search feature.
NAVIDEA BIOPHARMACEUTICALS - More news...
NAVIDEA BIOPHARMACEUTICALS - More news...
- Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel
- Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities
- Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination
- NYSE American to Commence Delisting Proceedings Against Navidea Biopharmaceuticals, Inc. (NAVB)
- Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer
- Navidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps Down
- Navidea Biopharmaceuticals, Inc. Rejects Unsolicited Offer To Acquire Certain Assets
- Navidea Biopharmaceuticals, Inc. Announces Distribution of Series K Preferred Stock to Holders of its Common Stock
- Navidea Biopharmaceuticals, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
- Navidea Biopharmaceuticals, Inc. Receives NYSE American Notice
- Navidea Biopharmaceuticals, Inc. Welcomes Jill Bieker Stefanelli, Ph.D. to Board of Directors; Alexander L. Cappello Steps Down
- Navidea Biopharmaceuticals, Inc. Investors Purchase $1.1 Million in Preferred Shares at Market
- Navidea Biopharmaceuticals, Inc. Promotes Michael Sherman Blue, M.D., FACEP, to Chief Medical Officer
- Navidea Biopharmaceuticals, Inc. Drives Strategy Forward, Shifts Approach for Communications
- Navidea Biopharmaceuticals, Inc. Announces Intent to sell Cardinal Milestone Payment for $8 Million; Secures New $2.75 Million Equity Line of Credit
- Navidea Biopharmaceuticals, Inc. Enters Asset Purchase Agreement with Meilleur Technologies, Inc. for Rights to NAV4694
- Navidea Biopharmaceuticals, Inc. Hires G2G Ventures as Executive Consultants; Chief Medical Officer Steps Down
- Navidea Biopharmaceuticals Reports Fourth Quarter 2022 Financial Results
- Navidea Biopharmaceuticals to Host Fourth Quarter 2022 Earnings Conference Call and Business Update
- Navidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent Application for Key Component of the Company’s Cancer Immunotherapy Pipeline
- Navidea Biopharmaceuticals Files Appeal in CRG Case
- Navidea Biopharmaceuticals Announces 50th Participant Enrolled in the Company’s Phase 3 Trial in Rheumatoid Arthritis
- Navidea Biopharmaceuticals Reports Third Quarter 2022 Financial Results
- Navidea Biopharmaceuticals Announces Details of Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting
- Navidea Biopharmaceuticals to Host Third Quarter 2022 Earnings Conference Call and Business Update
- Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting
- Navidea Biopharmaceuticals Appoints Joshua Wilson to the Board of Directors; Announces Dates Related to its 2022 Annual Meeting of Stockholders
- Navidea Biopharmaceuticals Announces Presentation of Results from its Two Phase 2B Clinical Trials in Rheumatoid Arthritis at Upcoming American College of Rheumatology Annual Meeting
- Navidea Biopharmaceuticals Announces Opening of Nine New Sites in its Pivotal Phase 3 Trial in Rheumatoid Arthritis and Termination of Binding Memorandum of Understanding with Jubilant Radiopharma
- Navidea Biopharmaceuticals Announces Oral Ruling in Case Involving Attorney’s Fees
